Cetuximab with radiotherapy in patients with loco-regionally advanced squamous cell carcinoma of head and neck unsuitable or ineligible for concurrent platinum-based chemo-radiotherapy: Ready for routine clinical practice

Indian Journal of Cancer

Volumn 48, Issue 2, 2011, Pages 148-153

  Agarwal, J P ^a   Gupta, T ^a   Kalyani, N ^a   Budrukkar, A ^a   Laskar, S G ^a   Murthy, V ^a   Kumar, P ^a   Narohna, V ^a   Pai, P ^a   Chaturvedi, P ^a   Dcruz, A K ^a  

^a TATA MEMORIAL HOSPITAL   (India)

Author keywords

Cetuximab; chemo radiotherapy; cisplatin; cost effectiveness; loco regionally advanced squamous cell carcinoma of the head and neck

Indexed keywords

CETUXIMAB; ANTINEOPLASTIC AGENT; CISPLATIN; MONOCLONAL ANTIBODY;

ADULT; AGED; ANAPHYLAXIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONFERENCE PAPER; DERMATITIS; DISEASE FREE SURVIVAL; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; LOADING DRUG DOSE; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTOR VARIABLE; RADIATION DOSE; RETROSPECTIVE STUDY; TREATMENT OUTCOME; ARTICLE; BRACHYTHERAPY; CHEMORADIOTHERAPY; COHORT ANALYSIS; FOLLOW UP; HEAD AND NECK TUMOR; MIDDLE AGED; PATHOLOGY; PROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRACHYTHERAPY; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; CISPLATIN; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84855720653     PISSN: 0019509X     EISSN: 19984774     Source Type: Journal    
DOI: 10.4103/0019-509X.82872     Document Type: Conference Paper

References (24)

1. Ferlay BF, Pisani PP. GLOBOCAN 2002: Cancer incidence, mortality and prevalence worldwide. IARC Cancer Base No. 5. Version 2.0. Lyon: IARC Press; 2004.
2. Shah JP, Lydiatt W. Treatment of cancer of the head and neck. CA Cancer J Clin 1995;45:352-68.
3. Winquist E, Oliver T, Gilbert R. Postoperative chemoradiotherapy for advanced squamous cell carcinoma of the head and neck: A systematic review with meta-analysis. Head Neck 2007;29:38-46.
4. Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data. MACHNC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 2000;355:949-55.
5. Pignon JP, le Maitre A, Maillard E, Bourhis J. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009;92:4-14.
6. Forastiere AA, Takasugi BJ, Baker SR, Wolf GT, Kudla-Hatch V. Highdose cisplatin in advanced head and neck cancer. Cancer Chemother Pharmacol 1987;19:155-8.
7. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003;21:2787-99.
8. Zimmermann M, Zouhair A, Azria D, Ozsahin M. The epidermal growth factor receptor (EGFR) in head and neck cancer: Its role and treatment implications. Radiat Oncol 2006;1:11.
9. Dassonville O, Formento JL, Francoual M, Ramaioli A, Santini J, Schneider M, et al. Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J Clin Oncol 1993;11:1873-8.
10. Ang KK, Berkey BA, Tu X, Zhang HZ, Katz R, Hammond EH, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002;62:7350-6.
11. Bonner JA, Maihle NJ, Folven BR, Christianson TJ, Spain K. The interaction of epidermal growth factor and radiation in human head and neck squamous cell carcinoma cell lines with vastly different radiosensitivities. Int J Radiat Oncol Biol Phys 1994;29:243-7.
12. Liang K, Ang KK, Milas L, Hunter N, Fan Z. The epidermal growth factor receptor mediates radioresistance. Int J Radiat Oncol Biol Phys 2003;57:246-54.
13. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567-78.
14. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010;11:21-8.
15. Giro C, Berger B, Bolke E, Ciernik IF, Duprez F, Locati L, et al. High rate of severe radiation dermatitis during radiation therapy with concurrent cetuximab in head and neck cancer: Results of a survey in EORTC institutes. Radiother Oncol 2009;90:166-71.
16. Bernier J, Bonner J, Vermorken JB, Bensadoun RJ, Dummer R, Giralt J, et al. Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck. Ann Oncol 2008;19:142-9.
17. Giovannini M, Gregorc V, Belli C, Roca E, Lazzari C, Vigano MG, et al. Clinical significance of skin toxicity due to EGFR-targeted therapies. J Oncol 2009;2009:849051.
18. Harrington KJ. Rash conclusions from a phase 3 study of cetuximab? Lancet Oncol 2010;11:2-3.
19. Koutcher L, Sherman E, Fury M, Wolden S, Zhang Z, Mo Q, et al. Concurrent cisplatin and radiation versus cetuximab and radiation for locally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2010.
20. Cetuximab plus radiotherapy versus cisplatin plus radiotherapy in locally advanced head and neck cancer. Available from: Http:// www.clinicaltrials.gov, No-NCT01216020[Last accessed on 2010 Sep 6].
21. Pfister DG, Su YB, Kraus DH, Wolden SL, Lis E, Aliff TB, et al. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: A pilot phase II study of a new combined-modality paradigm. J Clin Oncol 2006;24:1072-8.
22. Merlano M, Russi E, Benasso M, Corvo R, Colantonio I, Vigna- Taglianti R, et al. Cisplatin-based chemoradiation plus cetuximab in locally advanced head and neck cancer: A phase II clinical study. Ann Oncol 2011;22:712-7.
23. RTOG 0522: A randomized phase III trial of concurrent accelerated radiation and cisplatin versus concurrent accelerated radiation, cisplatin, and cetuximab [followed by surgery for selected patients] for Stage III and IV head and neck carcinomas. Clin Adv Hematol Oncol 2007;5:79-81.
24. Griffin S, Walker S, Sculpher M, White S, Erhorn S, Brent S, et al. Cetuximab plus radiotherapy for the treatment of locally advanced squamous cell carcinoma of the head and neck. Health Technol Assess 2009;13 Suppl 1:49-54.